Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 14, 1293-1308

Eravacycline: A New Treatment Option for Complicated Intra-Abdominal Infections in the Age of Multidrug Resistance

Affiliations

Eravacycline: A New Treatment Option for Complicated Intra-Abdominal Infections in the Age of Multidrug Resistance

Joseph S Solomkin et al. Future Microbiol.

Abstract

Aim: Recently approved for use in complicated intra-abdominal infection, eravacycline is a novel fluorocycline with broad spectrum of activity against resistant Gram-negative pathogens. This manuscript is a pooled analysis of two Phase III trials. Clinical efficacy: Clinical cure rates were 86.8% for eravacycline versus 87.6% for ertapenem, and 90.8% for eravacycline versus 91.2% for meropenem in the Intent to Treat (micro-ITT) populations, and 87.0% for eravacycline versus 88.8% ertapenem, and 92.4 versus 91.6% for meropenem in the Modified Intent to Treat (MITT) populations. Safety: Eravacycline is well tolerated, with lower rates of nausea, vomiting and diarrhea than other tetracyclines. Conclusion: Eravacycline is an effective new option for use in complicated intra-abdominal infections, and in particular, for the treatment of extended-spectrum β-lactamase- and carbapenem-resistant Enterobacteriaceae-expressing organisms.

Trial registration: ClinicalTrials.gov NCT01844856 NCT02784704.

Keywords: CRE; ESBL; Gram-negative; antibiotics; antimicrobial resistance; complicated intra-abdominal infection; eravacycline; tetracycline.

Similar articles

See all similar articles

Publication types

Associated data

LinkOut - more resources

Feedback